A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

Completed · Phase 4

Conditions studied: Breast Reduction

In brief

The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.

Key facts

Study ID

NCT05891613

Run by

Mayo Clinic

People needed

32

Starts

2024-01-24

Expected to finish

2025-10-06

Last updated by the study team

2025-12-15

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Adult female patients (18-70 years old) with symptomatic macromastia scheduled for breast reduction using a Wise pattern incision design.

You may not qualify if…

• Inability to provide informed consent
• Medical or surgical history precluding breast reduction
• History of significant chronic pain requiring daily use of opioid or nonopioid analgesics
• Pregnancy
• Concomitant non-breast surgical procedure
• Previous chest wall irradiation
• Previous breast implant, breast reduction or breast lift surgery
• Known allergy to bupivacaine or liposomal bupivacaine
• Liver or kidney dysfunction
• Use of antiplatelet or anticoagulation therapy.

Where it is running

• Mayo Clinic Minnesota — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.